IBDEI028 ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2456,1,8,0)
 ;;=8^Congenital Factor VII Disorder
 ;;^UTILITY(U,$J,358.3,2456,2)
 ;;=^27454
 ;;^UTILITY(U,$J,358.3,2457,0)
 ;;=286.1^^26^184^5
 ;;^UTILITY(U,$J,358.3,2457,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2457,1,1,0)
 ;;=1^286.1
 ;;^UTILITY(U,$J,358.3,2457,1,8,0)
 ;;=8^Cogenital Factor IX Disorder
 ;;^UTILITY(U,$J,358.3,2457,2)
 ;;=^27452
 ;;^UTILITY(U,$J,358.3,2458,0)
 ;;=286.2^^26^184^8
 ;;^UTILITY(U,$J,358.3,2458,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2458,1,1,0)
 ;;=1^286.2
 ;;^UTILITY(U,$J,358.3,2458,1,8,0)
 ;;=8^Congenital Factor XI Deficiency
 ;;^UTILITY(U,$J,358.3,2458,2)
 ;;=^27456
 ;;^UTILITY(U,$J,358.3,2459,0)
 ;;=286.3^^26^184^6
 ;;^UTILITY(U,$J,358.3,2459,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2459,1,1,0)
 ;;=1^286.3
 ;;^UTILITY(U,$J,358.3,2459,1,8,0)
 ;;=8^Congenital Def of Oth Clotting
 ;;^UTILITY(U,$J,358.3,2459,2)
 ;;=^27437
 ;;^UTILITY(U,$J,358.3,2460,0)
 ;;=286.4^^26^184^28
 ;;^UTILITY(U,$J,358.3,2460,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2460,1,1,0)
 ;;=1^286.4
 ;;^UTILITY(U,$J,358.3,2460,1,8,0)
 ;;=8^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,2460,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,2461,0)
 ;;=286.52^^26^184^2
 ;;^UTILITY(U,$J,358.3,2461,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2461,1,1,0)
 ;;=1^286.52
 ;;^UTILITY(U,$J,358.3,2461,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,2461,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,2462,0)
 ;;=286.59^^26^184^16
 ;;^UTILITY(U,$J,358.3,2462,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2462,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,2462,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,2462,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,2463,0)
 ;;=286.6^^26^184^10
 ;;^UTILITY(U,$J,358.3,2463,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2463,1,1,0)
 ;;=1^286.6
 ;;^UTILITY(U,$J,358.3,2463,1,8,0)
 ;;=8^Defibrination Syndrome
 ;;^UTILITY(U,$J,358.3,2463,2)
 ;;=^35673
 ;;^UTILITY(U,$J,358.3,2464,0)
 ;;=286.7^^26^184^1
 ;;^UTILITY(U,$J,358.3,2464,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2464,1,1,0)
 ;;=1^286.7
 ;;^UTILITY(U,$J,358.3,2464,1,8,0)
 ;;=8^Acquired Coagulation Factor Def
 ;;^UTILITY(U,$J,358.3,2464,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,2465,0)
 ;;=287.0^^26^184^3
 ;;^UTILITY(U,$J,358.3,2465,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2465,1,1,0)
 ;;=1^287.0
 ;;^UTILITY(U,$J,358.3,2465,1,8,0)
 ;;=8^Allergic Purpura
 ;;^UTILITY(U,$J,358.3,2465,2)
 ;;=^101365
 ;;^UTILITY(U,$J,358.3,2466,0)
 ;;=287.1^^26^184^22
 ;;^UTILITY(U,$J,358.3,2466,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2466,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,2466,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,2466,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,2467,0)
 ;;=287.2^^26^184^17
 ;;^UTILITY(U,$J,358.3,2467,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2467,1,1,0)
 ;;=1^287.2
 ;;^UTILITY(U,$J,358.3,2467,1,8,0)
 ;;=8^Oth Nonthrombocytopenic Purpuras
 ;;^UTILITY(U,$J,358.3,2467,2)
 ;;=^87741
 ;;^UTILITY(U,$J,358.3,2468,0)
 ;;=287.31^^26^184^13
 ;;^UTILITY(U,$J,358.3,2468,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2468,1,1,0)
 ;;=1^287.31
 ;;^UTILITY(U,$J,358.3,2468,1,8,0)
 ;;=8^Immune Thrombocytopenic Purpura
 ;;^UTILITY(U,$J,358.3,2468,2)
 ;;=^332746
 ;;^UTILITY(U,$J,358.3,2469,0)
 ;;=287.32^^26^184^11
 ;;^UTILITY(U,$J,358.3,2469,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2469,1,1,0)
 ;;=1^287.32
 ;;^UTILITY(U,$J,358.3,2469,1,8,0)
 ;;=8^Evan's Syndrome
 ;;^UTILITY(U,$J,358.3,2469,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,2470,0)
 ;;=287.41^^26^184^20
 ;;^UTILITY(U,$J,358.3,2470,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2470,1,1,0)
 ;;=1^287.41
 ;;^UTILITY(U,$J,358.3,2470,1,8,0)
 ;;=8^Posttransfusion Purpura
 ;;^UTILITY(U,$J,358.3,2470,2)
 ;;=^339609
 ;;^UTILITY(U,$J,358.3,2471,0)
 ;;=287.49^^26^184^18
 ;;^UTILITY(U,$J,358.3,2471,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2471,1,1,0)
 ;;=1^287.49
 ;;^UTILITY(U,$J,358.3,2471,1,8,0)
 ;;=8^Oth Secondary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,2471,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,2472,0)
 ;;=287.8^^26^184^19
 ;;^UTILITY(U,$J,358.3,2472,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2472,1,1,0)
 ;;=1^287.8
 ;;^UTILITY(U,$J,358.3,2472,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,2472,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,2473,0)
 ;;=287.9^^26^184^27
 ;;^UTILITY(U,$J,358.3,2473,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2473,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,2473,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,2473,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,2474,0)
 ;;=238.72^^26^184^14
 ;;^UTILITY(U,$J,358.3,2474,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2474,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,2474,1,8,0)
 ;;=8^Low Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,2474,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,2475,0)
 ;;=238.73^^26^184^12
 ;;^UTILITY(U,$J,358.3,2475,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2475,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,2475,1,8,0)
 ;;=8^Hi Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,2475,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,2476,0)
 ;;=238.75^^26^184^15
 ;;^UTILITY(U,$J,358.3,2476,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2476,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,2476,1,8,0)
 ;;=8^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,2476,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,2477,0)
 ;;=205.00^^26^185^32
 ;;^UTILITY(U,$J,358.3,2477,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2477,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,2477,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2477,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,2478,0)
 ;;=205.01^^26^185^31
 ;;^UTILITY(U,$J,358.3,2478,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2478,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,2478,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2478,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,2479,0)
 ;;=205.10^^26^185^18
 ;;^UTILITY(U,$J,358.3,2479,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2479,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,2479,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,2479,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,2480,0)
 ;;=205.11^^26^185^17
 ;;^UTILITY(U,$J,358.3,2480,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2480,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,2480,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,2480,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,2481,0)
 ;;=289.0^^26^185^50
 ;;^UTILITY(U,$J,358.3,2481,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2481,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,2481,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,2481,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,2482,0)
 ;;=238.4^^26^185^48
 ;;^UTILITY(U,$J,358.3,2482,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2482,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,2482,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,2482,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,2483,0)
 ;;=288.9^^26^185^67
 ;;^UTILITY(U,$J,358.3,2483,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2483,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,2483,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,2483,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,2484,0)
 ;;=289.81^^26^185^49
 ;;^UTILITY(U,$J,358.3,2484,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2484,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,2484,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,2484,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,2485,0)
 ;;=238.75^^26^185^29
 ;;^UTILITY(U,$J,358.3,2485,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2485,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,2485,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,2485,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,2486,0)
 ;;=289.9^^26^185^66
 ;;^UTILITY(U,$J,358.3,2486,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2486,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,2486,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,2486,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,2487,0)
 ;;=205.02^^26^185^30
 ;;^UTILITY(U,$J,358.3,2487,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2487,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,2487,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2487,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,2488,0)
 ;;=205.12^^26^185^16
 ;;^UTILITY(U,$J,358.3,2488,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2488,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,2488,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,2488,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,2489,0)
 ;;=205.20^^26^185^59
 ;;^UTILITY(U,$J,358.3,2489,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2489,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,2489,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,2489,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,2490,0)
 ;;=205.21^^26^185^58
 ;;^UTILITY(U,$J,358.3,2490,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2490,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,2490,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,2490,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,2491,0)
 ;;=205.22^^26^185^57
 ;;^UTILITY(U,$J,358.3,2491,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2491,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,2491,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,2491,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,2492,0)
 ;;=205.30^^26^185^35
 ;;^UTILITY(U,$J,358.3,2492,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2492,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,2492,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,2492,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,2493,0)
 ;;=205.31^^26^185^34
 ;;^UTILITY(U,$J,358.3,2493,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2493,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,2493,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
